The estimated Net Worth of Daniel Newman Mendelson is at least $1.03 Milhão dollars as of 12 January 2024. Mr. Mendelson owns over 1,000 units of Champions Oncology Inc stock worth over $808,404 and over the last 12 years he sold CSBR stock worth over $177,246. In addition, he makes $41,020 as Independent Director at Champions Oncology Inc.
Daniel has made over 33 trades of the Champions Oncology Inc stock since 2014, according to the Form 4 filled with the SEC. Most recently he bought 1,000 units of CSBR stock worth $6,500 on 12 January 2024.
The largest trade he's ever made was buying 750,000 units of Champions Oncology Inc stock on 11 March 2015 worth over $3,052,500. On average, Daniel trades about 21,836 units every 78 days since 2013. As of 12 January 2024 he still owns at least 198,625 units of Champions Oncology Inc stock.
You can see the complete history of Mr. Mendelson stock trades at the bottom of the page.
Daniel N. Mendelson serves as Independent Director of the Company. Mr. Mendelson is Operating Partner at Welsh Carson, a private equity firm. He is also presently Advisor to Avalere Health, a healthcare advisory and analytics, that he Founded in 2000 and sold to Inovalon Holdings in 2015. The firm’s customer base includes Fortune 500 healthcare companies, provider organizations, medical foundations and government. Mr. Mendelson is also an Executive in Residence of the Fuqua School of Business at Duke University, and sits on the board of Centrexion, a private company focused on non-addictive alternatives to opioid therapies. From 1998 to 2000, Mr. Mendelson served as associate director for health at the Office of Management and Budget (OMB). Prior to joining OMB, Mr. Mendelson was senior vice president of The Lewin Group and director of the medical technology practice. He holds an undergraduate degree in economics from Oberlin College, and a MPP from the Kennedy School of Government at Harvard University. He previously served on the boards of Coventry Healthcare (sold to Aetna in 2013), PharMerica Corporation (NYSE: PMC) and HMS holdings (NASDAQ: HMSY).
As the Independent Director of Champions Oncology Inc, the total compensation of Daniel Mendelson at Champions Oncology Inc is $41,020. There are 5 executives at Champions Oncology Inc getting paid more, with Ronnie Morris having the highest compensation of $1,343,650.
Daniel Mendelson is 55, he's been the Independent Director of Champions Oncology Inc since 2013. There are 3 older and 4 younger executives at Champions Oncology Inc. The oldest executive at Champions Oncology Inc is Abba Poliakoff, 68, who is the Independent Director.
Daniel's mailing address filed with the SEC is C/O CHAMPIONS ONCOLOGY, INC., ONE UNIVERSITY PLAZA, SUITE 307, HACKENSACK, NJ, 07601.
Over the last 21 years, insiders at Champions Oncology Inc have traded over $9,072,751 worth of Champions Oncology Inc stock and bought 42,104,566 units worth $13,657,266 . The most active insiders traders include Ventures Ix, L.P.Battery In..., Michael Maurice Brown, eSports Inc Champions. On average, Champions Oncology Inc executives and independent directors trade stock every 76 days with the average trade being worth of $2,196,294. The most recent stock trade was executed by Daniel Newman Mendelson on 12 January 2024, trading 1,000 units of CSBR stock currently worth $6,500.
champions oncology, inc. is engaged in the development of advanced technology solutions to personalize the development and use of oncology drugs. champions tumorgraft™ technology platform is a novel approach to personalizing cancer care based upon the implantation of human tumors in immune deficient mice followed by propagation of the resulting engraftments, or tumorgrafts, in a manner that preserves the biological characteristics of the original human tumor. champions believes that these tumorgrafts, unlike cell line derived xenografts used in tradition testing, closely reflect human cancer biology and their response to drugs is predictive of clinical outcomes in cancer patients. the company offers personalized tumorgraft development, drug studies and genome sequencing as part of its personalized oncology solutions ("pos") whereby physicians can evaluate the effects of cancer drugs on their patients' tumorgrafts and understand the genetic make-up of their patient's tumor enabling them
Champions Oncology Inc executives and other stock owners filed with the SEC include: